Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis-Reference-Cited by-同舟云学术

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

Published:2021-06 Issue:9 Volume:23 Page:2058-2066
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Mann Johannes F. E.¹²^ORCID,Buse John B.³,Idorn Thomas⁴,Leiter Lawrence A.⁵,Pratley Richard E.⁶,Rasmussen Søren⁴,Vilsbøll Tina⁷⁸⁹,Wolthers Benjamin⁴,Perkovic Vlado¹⁰

Affiliation:

1. Department of Nephrology Friedrich Alexander University of Erlangen Erlangen Germany

2. KfH Kidney Centre Munich Germany

3. University of North Carolina School of Medicine Chapel Hill North Carolina USA

4. Novo Nordisk A/S Søborg Denmark

5. Li Ka Shing Knowledge Institute, St. Michael's Hospital University of Toronto Toronto Ontario Canada

6. AdventHealth Translational Research Institute Orlando Florida USA

7. Steno Diabetes Centre Copenhagen Gentofte Denmark

8. Gentofte Hospital Hellerup Denmark

9. University of Copenhagen Copenhagen Denmark

10. The George Institute, UNSW Sydney New South Wales Australia

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14443

Reference35 articles.

1. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes

2. United States Renal Data System.Annual data report. Chapter 7: healthcare expenditures for persons with CKD.2018.https://www.usrds.org/2018/view/v1_07.aspx(Accessed September 2020).

3. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

4. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016

5. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide;Diabetes, Obesity and Metabolism;2024-09-02

2. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes;New England Journal of Medicine;2024-07-11

3. The glucagon‐like peptide‐1 receptor agonist semaglutide in diabetic kidney disease: A new kid on the block to afford maximal kidney protection;European Journal of Clinical Investigation;2024-07-09

4. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6;Nephrology Dialysis Transplantation;2024-07-02

5. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91);The Lancet;2024-07